Retatrutide is an investigational drug. Its effectiveness has not been established, and we do not publish outcome figures for drugs under investigation. Here is the reasoning, and what the trial process does and does not settle.
If you are searching for retatrutide weight loss results, you will find numbers quoted in plenty of places. You will not find them here, and that is deliberate.
Retatrutide is an investigational drug: it may be used only in clinical research, and its effectiveness has not been established for any use. FDA regulation governing investigational drugs (21 CFR 312.7) prohibits representing such a drug as effective for the purpose under investigation. Publishing an outcome figure beside a drug name is that representation, whatever caveats surround it.
This is not a claim that the research is uninteresting or that the figures are fabricated. It is that a number produced by a trial still in progress is not a finding about what a drug does for patients, and presenting it as though it were misleads the person reading it.
A figure from a clinical trial describes what happened to a specific group of participants, selected against specific criteria, over a specific period, measured against a specific endpoint. It is evidence submitted for review. It is not a property of the drug.
That distinction is the entire reason drug development runs in phases. Earlier trials are small and short. They can indicate a direction; they are not sized to confirm one, to detect uncommon harms, or to describe what happens over longer exposure. Drugs have been discontinued at every stage of development after larger studies changed the picture.
A figure becomes a statement about what a drug does only once the full programme is complete and a regulator has independently reviewed the underlying data. For retatrutide, that has not happened.
Retatrutide is in Phase 3 trials conducted by Eli Lilly. Phase 3 is the final stage of clinical testing before a sponsor may submit a New Drug Application.
Eli Lilly has not announced a submission date, and the FDA has not approved retatrutide for any indication. Being in Phase 3 describes where testing currently stands; it does not indicate that approval is near or that it is likely.
Retatrutide cannot lawfully be prescribed, dispensed, or compounded, and Weight Method does not offer it.
Numbers attributed to retatrutide circulate widely, including on sites selling products under that name. A few things are worth holding on to.
A figure quoted with no trial, no population, no duration, and no endpoint attached cannot be checked by anyone, and most circulated figures have been stripped of all four.
A vendor quoting trial outcomes is using research conducted by somebody else to sell a product that is not the article that was studied. Whatever was in the trial vial, it is not what is in theirs: nobody has verified the identity, purity, potency, or sterility of anything sold under this name.
If you want primary sources rather than summaries, the peer-reviewed literature and ClinicalTrials.gov are public. Both are records of research in progress, not treatment guidance, and neither is a substitute for talking to a clinician.
Retatrutide is not an option, so waiting on it is not a plan. There is no assurance it will be approved and none about when.
If weight management is the goal, the productive step is a conversation with a licensed provider about the options that are lawfully available today and whether any of them fits your health history.